Imaging study of new agent for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This study tests a new imaging agent (a special dye) that might help doctors see tumors more clearly in people with certain advanced cancers. You would receive the dye and then have scans to see if it highlights cancer areas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer, head and neck cancer, non-small cell lung cancer, or triple-negative breast cancer that has spread or cannot be cured with surgery.
- You have tried standard treatments and they have stopped working, or you are not eligible to receive them.
- You have at least one area of cancer that shows up on a recent CT or MRI scan.
- You can provide a sample of your tumor tissue from a previous biopsy or surgery.
- You are generally able to take care of yourself and do most daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent, 64Cu-LNTH-1363S, to see if it can find certain sarcomas and gastrointestinal cancers. The goal is to help doctors better see where your cancer is and plan the best treatment. You may be eligible if you have a sarcoma or a GI cancer and are willing to have a tumor tissue sample taken.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Hear when a new Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.